On Monday, July 30, Intellipharmaceuticals settled “patent infringement claims brought by AstraZeneca Pharmaceuticals LP over plans to market a generic version of anti-psychotic drug Seroquel XR®, agreeing to delay the launch of its version and admit the legitimacy of AstraZeneca’s Seroquel® patents.” AstraZeneca is represented by Finnegan in this matter.
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Commentary
How I Made It to Law Firm Leadership: 'Devote Time to Initiatives That Improve the Firm'
November 13, 2023
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.